| |
Focused on accelerating gene and cell therapy from clinical to commercial, OcyonBio built two processing facilities in Puerto Rico. See how the company is now benefiting from the island's highly skilled talent, tax benefits & much more. 
|
|
Today’s Big NewsMar 4, 2024 |
| By Fraiser Kansteiner A little more than half a year after winning a historic over-the-counter nod, Perrigo’s nonprescription birth control pill Opill is set to hit store shelves in the “coming weeks.” |
|
|
|
By James Waldron With the FDA mulling whether to approve BridgeBio’s acoramidis as a rival to Pfizer’s blockbuster heart disease drug Vyndaqel, Bayer has decided to pay out $310 million to scoop up the European rights. |
By Conor Hale It’s one thing to design an experiment that succeeds in the lab. It’s another to design one that works in every lab—and every hospital, every doctor’s office, every home, or in the hands of every surgeon, every nurse and every patient. |
By Kevin Dunleavy Less than three months after completing its $43 billion acquisition of Seagen, Pfizer has confirmed a report that it is shutting down construction of a $350 million manufacturing facility in Everett, Washington. The decision will affect 120 employees working on the initial setup of the site, the company said. |
|
Wednesday, March 13, 2024 | 11am ET / 8am PT Extractables and leachables are a hot topic in the pharmaceutical industry today. As single-use systems, devices, and routes of administration evolve, it is important to have a strategy that helps ensure you choose proper equipment and materials, file on time, avoid repeat studies, and more. Save your spot to be a part of this insightful discussion! 
|
|
By Max Bayer Apparently C4 Therapeutics' protein degradation tech brings all the Mercks to the yard. The Massachusetts biotech has signed on Merck KGaA in a $740 million biobucks partnership to find two degraders for cancer. |
By Conor Hale Baxter disclosed that its long-gestating plans to spin out its dialysis care operations into an independent company may be dropped, in favor of a sale later this year. |
By James Waldron The notoriously tricky indication of Alzheimer’s disease has defeated another candidate, with Vivoryon Therapeutic’s lead asset missing all endpoints in a phase 2 trial and sending the company’s stock plunging 90%. |
By Angus Liu Johnson & Johnson continues to grow its oncology franchise with a new FDA approval that opens the lung cancer drug Rybrevant to treating certain newly diagnosed patients. |
By Conor Hale Boston Scientific has received FDA approval for its Agent drug-coated balloon sized to fit within blocked or constricted coronary arteries, nearly a decade after it made its European debut. |
By Zoey Becker After a preliminary analysis found a potentially higher risk of Guillain-Barré syndrome following RSV vaccination in older adults, GSK and Pfizer said they will conduct further safety studies. |
By Conor Hale The OsteoCool 2.0 system delivers radiofrequency ablation to treat bone tumors, including cancer metastases as well as benign lesions such as osteoid osteomas. |
By Gabrielle Masson,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
Fierce podcasts Don’t miss an episode |
| The FDA recently asked the six marketed CAR-T therapies to add a new boxed warning item on their labels to reflect the risk of secondary T-cell cancers. This week on "The Top Line," Fierce Pharma’s Angus Liu talks with regulatory experts to understand the rationale behind the FDA’s decision and to discuss its implications for CAR-T candidates and their developers down the line. |
|
|---|
|
|
|
Thursday, March 28, 2024 | 11am ET / 8am PT Building a solid foundation and getting support in your journey, from critical raw materials to commercial supply, through flexible and transparent partnerships can be key in your scalable success. Don't miss this opportunity to learn how to optimize your gene therapy development. Register now. 
|
|
Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
